Drug-delivery systems maker Echo Therapeutics(NASDAQ:ECTE) launched clinical trials for its Symphony transdermal continuous glucose monitoring system.
Echo plans to enroll up to 25 patients with either Type I or Type II diabetes and compare the Symphony system to two other glucose analyzers on the market.
The company expects to complete and announce the results of the study in its fourth quarter.